Academic literature on the topic 'Bureau of Data and Research'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bureau of Data and Research.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Bureau of Data and Research"
1
Ostry, Sylvia. "Comparative Research Approaches." Relations industrielles 21, no. 4 (2005): 511–17. http://dx.doi.org/10.7202/027728ar.
Full textAbstract:
In the minds of many people, the Dominion Bureau of Statistics appears as a kind of factory producing data. It is more than that. This paper shows that the Bureau is taking new leads in the field of developmental and analytical research bearing on revised and new statistical series.
2
Ruggles, Steven, Catherine Fitch, Diana Magnuson, and Jonathan Schroeder. "Differential Privacy and Census Data: Implications for Social and Economic Research." AEA Papers and Proceedings 109 (May 1, 2019): 403–8. http://dx.doi.org/10.1257/pandp.20191107.
Full textAbstract:
The Census Bureau has announced new methods for disclosure control in public use data products. The new approach, known as differential privacy, represents a radical departure from current practice. In its pure form, differential privacy techniques may make the release of useful microdata impossible and limit the utility of tabular small-area data. Adoption of differential privacy will have far-reaching consequences for research. It is likely that scientists, planners, and the public will lose the free access we have enjoyed for six decades to reliable public Census Bureau data describing US social and economic change.
3
Kuhnl, Andrea, Claire Roddie, Nuria Martinez-Cibrian, et al. "Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England." Blood 134, Supplement_1 (2019): 767. http://dx.doi.org/10.1182/blood-2019-124177.
Full textAbstract:
Background After European Medicines Agency (EMA) approval of axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory (r/r) high-grade lymphoma in 2018, England was one of the first European countries granting fully funded access to these CD19 CAR-T therapies. Both products are available through the National Health Service England (NHSE) Cancer Drug Fund until their cost-effectiveness has been determined. The NHSE CAR-T program has been set up in a structure aiming to implement robust and transparent criteria for patient selection and to ensure equity of treatment access: CAR-T slots are approved by a weekly National CAR-T Clinical Panel (NCCP), consisting of independent clinical experts, patient representatives, and delegates from each CAR-T centre; treatment is delivered in 7 geographically spread commissioned CAR-T centres (Birmingham, Bristol, King's College Hospital London, University Hospital London, The Christie Manchester, Manchester Royal Infirmary, Newcastle). Here, we report prospective data on the first 122 lymphoma patients approved by the NCCP. Methods Patients with r/r high-grade lymphoma referred to the NCCP between December 2018 and July 2019 and deemed eligible for treatment with CD19 CAR-T were analysed. Eligibility was assessed in the CAR-T centre's tumor board, based on organ function and fitness (performance status 0/1), absence of active CNS disease, and biopsy confirmation of r/r high-grade lymphoma. The final decision on patient eligibility was made by consensus through the NCCP independent clinical panel. CAR-T product selection for each patient was done by the CAR-T centre, mainly on the basis of manufacturing slot availability. Results 122 patients were approved for treatment with CD19 CAR-T therapy by the panel. CAR-T centres selected 76 patients for axicabtagene ciloleucel and 46 for tisagenlecleucel. Patients' median age was 56 years (range 18-75). 62% were male. 87 (71%) patients had de novo diffuse large B-cell lymphoma, 29 (24%) transformed lymphoma (23 from follicular- and 6 from marginal zone lymphoma), and 6 (5%) primary mediastinal B-cell lymphoma. 96 (79%) patients had biopsy confirmation of disease prior to submission. 71 (58%) patients had received 2 prior lines of therapy for high-grade lymphoma, 51 (42%) patients 3 or more treatment lines (maximum 6). 5 patients had previous allogeneic, 19 previous autologous transplant. 88% of patients (107/122) were refractory to the last line of treatment (stable- or progressive disease (PD) or relapse within 6 months). Among 122 patients, 112 completed leukapheresis, 3 are awaiting the procedure, and 7 patients did not proceed (6 due to PD, 1 opted for radical radiotherapy). 57 of 112 patients were infused at the time of abstract submission, 42 are awaiting CAR-T infusion. 10 patients did not proceed to infusion due to disease progression and clinical deterioration (3 with CNS relapse), 2 due to manufacturing failure. One patient achieved a complete response following bridging therapy and is currently monitored. 84% (88/105) patients received bridging therapy between the time of NCCP approval and CAR-T infusion (median 64 days), 62 had chemotherapy, 9 radiotherapy, and 17 steroids only. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time approximately 62 patients will have completed their 3 months PET response assessment. Conclusion NHSE has successfully implemented a national structure for providing licenced CAR-T products in England, enabling equity of access and oversight on capacity and patient outcomes, which can serve as a model for newly licenced, cost-intense and complex cell- and gene therapies in the future. The prospective and centralised nature of this dataset offers a true reflection of the real-world patient population undergoing CAR-T therapy in England. Disclosures Kuhnl: Kite Gilead: Honoraria. Roddie:Gilead: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Novartis: Consultancy. Menne:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Kite/Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Kyowa Kirin: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Daiichi Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau. Sanderson:Kite/Gilead: Honoraria. Osborne:Novartis: Other: Travel; Pfizer: Honoraria, Speakers Bureau; MSD: Consultancy; Takeda: Consultancy, Honoraria, Other: Travel, Speakers Bureau; Roche: Consultancy, Honoraria, Other: Travel, Speakers Bureau; Servier: Consultancy; Gilead: Consultancy. Radford:AstraZeneca: Equity Ownership, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Research Funding; GSK: Equity Ownership; Seattle Genetics: Consultancy, Honoraria. Patten:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria; Roche: Honoraria, Research Funding. O'Reilly:Kite Gilead: Honoraria. Bloor:Abvie, Gilead, Novartis, Autolus, Celgene, etc: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational grant. Rowntree:Novartis: Consultancy. Bowles:Abbvie: Research Funding; Janssen: Research Funding. Collins:Gilead: Consultancy, Honoraria. McMillan:BMS: Honoraria; Celgene: Honoraria, Speakers Bureau; F. Hoffmann-La Roche Ltd: Honoraria, Speakers Bureau; Gilead: Honoraria; Novartis: Honoraria; Sandoz: Honoraria; Pfizer: Honoraria, Research Funding; MSD: Honoraria.
4
Yang, Junda, Yun Xia, Liu Yang, and Zhongtao Zhang. "Research on “First-Class” Financial Management of Power Grid Enterprises Based on IPA: Taking XX Power Supply Bureau as an Example." Journal of Management and Sustainability 8, no. 4 (2018): 74. http://dx.doi.org/10.5539/jms.v8n4p74.
Full textAbstract:
Using the data collected by the questionnaire survey, this paper uses IPA (importance performance analysis) to analyze the financial performance and operation status of some financial data of the XX power supply bureau, and finds the indicators that need to maintain the advantages and the indicators that need to be improved. It can provide reference for the construction of power supply bureaus and power companies to create first-class indicators.
5
Miesbach, Wolfgang A., Giovanni Di Minno, Elena Santagostino, et al. "Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data." Blood 134, Supplement_1 (2019): 1117. http://dx.doi.org/10.1182/blood-2019-128486.
Full textAbstract:
Background: The availability of factor (F)VIII replacement products has dramatically improved life expectancy for patients with hemophilia A (HA). However, older patients face distinct challenges. Age-related comorbidities such as cardiovascular disease (CVD), often involving treatments that can increase the risk of bleeding, and patients who received treatment before the advent of recombinant products, are more likely to have been exposed to blood-borne viruses carrying chronic infections. It is important to understand clinical outcomes with FVIII products in patients with HA and these comorbidities. BAY 94-9027 (damoctocog alfa pegol; Jivi) is a B-domain deleted recombinant FVIII, site-specifically PEGylated with a 60 kDa (2×30 kDa) polyethylene glycol to extend its half-life. Efficacy and safety of BAY 94-9027 as prophylactic and on-demand therapy for patients with severe HA were demonstrated in the phase II/III PROTECT VIII trial and its Extension. This post hoc analysis assessed bleeding rates and safety outcomes for prophylaxis patients in PROTECT VIII and its Extension, based on the presence or absence of comorbidities of interest. Patients/Methods: PROTECT VIII (NCT01580293) was a partially randomized, open-label trial of 134 males aged 12-65 years with severe HA (FVIII <1%) and ≥150 FVIII exposure days. Prophylaxis patients (n=114) received BAY 94-9027 25 IU/kg twice weekly (2×W) for a 10-week run-in period. Patients with ≤1 spontaneous joint or muscle bleed during this period were randomized to 45-60 IU/kg every 5 days or 60 IU/kg every 7 days for the main 26-week study; patients enrolling after the randomization arms were full, or with ≥2 bleeds in the run-in period, received 30-40 IU/kg 2×W. Patients completing the main study could enter an extension, continuing BAY 94-9027 on any regimen used in the main study. Baseline characteristics, annualized bleeding rates (ABR) and safety were examined for patients on prophylaxis treatment during main study and its Extension with and without comorbidities of interest. Comorbidities included human immunodeficiency virus (HIV) infection, hepatitis B or C infection (HBV or HCV), and risk factors for CVD (hypertension, hypercholesterolemia, hypertriglyceridemia and hyperlipidemia). Results: A total of 104 patients who received BAY 94-9027 prophylaxis during the main study and the Extension (data cut-off: Jan 2018) were included in this analysis. Mean (SD) age of patients was 34.3 (13.0) years with a median (Q1;Q3) of 7 (2;15) bleeds in the 12 months before enrolment. Most patients (72.1%) had target joint(s) at baseline. Before study, 22 (21.2%) patients were receiving on-demand treatment; the remaining 82 were on regular prophylaxis. Most patients (n=66, 63.5%) had ≥1 comorbidity of interest. Of those, chronic HCV infection (HCV detection, asymptomatic) was most common (40/66, 60.6%), followed by acute HCV infection (HCV detection, symptomatic, 26/66, 39.4%), HBV infection (20/66, 30.3%), hypertension (17/66, 25.8%), hyperlipidemia (7/66, 10.6%), HIV infection (5/66, 7.6%), and hypertriglyceridemia (2/66, 3.0%). Patients with comorbidities of interest were older (mean age: 41.5 vs 21.9 years, respectively) and had a higher median (Q1;Q3) number of joint bleeds in the previous 12 months (5 [1;12] vs 3 [0;10], respectively) than patients without comorbidities (n=38). Pre-study, median ABR was 6.0 and 7.0 in patients with and without comorbidities of interest respectively, which decreased to 2.9 and 1.5 respectively during the main study, and further to 1.8 and 1.2 respectively during the Extension (Figure). In all patients with comorbidities of interest, robust improvements in median ABR were observed between the 12-month pre-study period and the main study period, and were maintained or improved in the Extension. Patients with comorbidities of interest had similar numbers of drug-related adverse events (AEs; 10.6% vs 23.7%), serious AEs (39.4% vs 28.9%) and discontinuations due to AEs (1.5% vs 2.6%) than those without comorbidities of interest during main study and Extension. Conclusions: The majority of patients (63.5%) in PROTECT VIII had ≥1 comorbidity of interest. The results from this post hoc analysis indicate that long-term BAY 94-9027 prophylaxis provided excellent control of bleed rates and was well tolerated in patients with severe HA and comorbidities of interest: HIV, HBV or HCV infection or risk factors for CVD. Figure Disclosures Miesbach: Biotest: Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria; Freeline: Honoraria; Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Honoraria, Research Funding, Speakers Bureau; Grifols: Speakers Bureau; Biomarin: Consultancy, Honoraria; LFB: Consultancy, Honoraria, Research Funding, Speakers Bureau; Sobi: Consultancy, Honoraria, Research Funding, Speakers Bureau; UniQure: Consultancy, Honoraria, Research Funding; CSL: Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Bayer: Research Funding, Speakers Bureau; Octapharma: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau. Di Minno:Sanofi: Speakers Bureau; Bayer: Consultancy, Honoraria, Speakers Bureau; Kedrion: Speakers Bureau; CSL: Speakers Bureau; Pfizer: Speakers Bureau; Novo Nordisk: Speakers Bureau. Santagostino:Roche: Consultancy, Speakers Bureau; Octapharma: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Spark: Speakers Bureau; Kedrion: Consultancy, Speakers Bureau; Bioverativ: Consultancy, Speakers Bureau; UniQure: Consultancy, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Novo Nordisk: Consultancy, Speakers Bureau; Grifols: Consultancy, Speakers Bureau; Bayer: Consultancy, Speakers Bureau; Shire: Consultancy, Speakers Bureau; CSL: Consultancy, Speakers Bureau; Sanofi: Speakers Bureau. Klamroth:Bayer, Biomarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, SOBI, Takeda: Consultancy; Bayer, Novo Nordisk, SOBI: Research Funding. Bayh:Bayer: Employment. Soto:Bayer: Employment. Hermans:LFB: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau; Octapharma: Consultancy, Honoraria, Speakers Bureau; Bayer: Consultancy, Honoraria, Speakers Bureau; Shire: Consultancy, Honoraria, Speakers Bureau; CAF-DCF: Consultancy, Honoraria, Speakers Bureau; Novo Nordisk: Consultancy, Honoraria, Speakers Bureau; CSL: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Kedrion: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau.
6
Courvoisier, D., K. Lauper, S. A. Bergstra, et al. "OP0199 POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 124–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1162.
Full textAbstract:
Background:Comparing drug effectiveness in observational settings is hampered by several major threats, among them confounding and attrition bias bias (patients who stop treatment no longer contribute information, which may overestimate true drug effectiveness).Objectives:To present points to consider (PtC) when analysing and reporting comparative effectiveness with observational data in rheumatology (EULAR-funded taskforce).Methods:The task force comprises 18 experts: epidemiologists, statisticians, rheumatologists, patients, and health professionals.Results:A systematic literature review of methods currently used for comparative effectiveness research in rheumatology and a statistical simulation study were used to inform the PtC (table). Overarching principles focused on defining treatment effectiveness and promoting robust and transparent epidemiological and statistical methods increase the trustworthiness of the results.Points to considerReporting of comparative effectiveness observational studies must follow the STROBE guidelinesAuthors should prepare a statistical analysis plan in advanceTo provide a more complete picture of effectiveness, several outcomes across multiple health domains should be comparedLost to follow-up from the study sample must be reported by the exposure of interestThe proportion of patients who stop and/or change therapy over time, as well as the reasons for treatment discontinuation must be reportedCovariates should be chosen based on subject matter knowledge and model selection should be justifiedThe study baseline should be at treatment initiation and a description of how covariate measurements relate to baseline should be includedThe analysis should be based on all patients starting a treatment and not limited to patients remaining on treatment at a certain time pointWhen treatment discontinuation occurs before the time of outcome assessment, this attrition should be taken into account in the analysis.Sensitivity analyses should be undertaken to explore the influence of assumptions related to missingness, particularly in case of attritionConclusion:The increased use of real-world comparative effectiveness studies makes it imperative to reduce divergent or contradictory results due to biases. Having clear recommendations for the analysis and reporting of these studies should promote agreement of observational studies, and improve studies’ trustworthiness, which may also facilitate meta-analysis of observational data.Disclosure of Interests:Delphine Courvoisier: None declared, Kim Lauper: None declared, Sytske Anne Bergstra: None declared, Maarten de Wit Grant/research support from: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Consultant of: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Speakers bureau: Dr. de Wit reports personal fees from Ely Lilly, 2019, personal fees from Celgene, 2019, personal fees from Pfizer, 2019, personal fees from Janssen-Cilag, 2017, outside the submitted work., Bruno Fautrel Grant/research support from: AbbVie, Lilly, MSD, Pfizer, Consultant of: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Lilly, Janssen, Medac MSD France, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi Aventis, SOBI and UCB, Thomas Frisell: None declared, Kimme Hyrich Grant/research support from: Pfizer, UCB, BMS, Speakers bureau: Abbvie, Florenzo Iannone Consultant of: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Speakers bureau: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Joanna KEDRA: None declared, Pedro M Machado Consultant of: PMM: Abbvie, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Speakers bureau: PMM: Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Lykke Midtbøll Ørnbjerg Grant/research support from: Novartis, Ziga Rotar Consultant of: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Speakers bureau: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Maria Jose Santos Speakers bureau: Novartis and Pfizer, Tanja Stamm Grant/research support from: AbbVie, Roche, Consultant of: AbbVie, Sanofi Genzyme, Speakers bureau: AbbVie, Roche, Sanofi, Simon Stones Consultant of: I have been a paid consultant for Envision Pharma Group and Parexel. This does not relate to this abstract., Speakers bureau: I have been a paid speaker for Actelion and Janssen. These do not relate to this abstract., Anja Strangfeld Speakers bureau: AbbVie, BMS, Pfizer, Roche, Sanofi-Aventis, Robert B.M. Landewé Consultant of: AbbVie; AstraZeneca; Bristol-Myers Squibb; Eli Lilly & Co.; Galapagos NV; Novartis; Pfizer; UCB Pharma, Axel Finckh Grant/research support from: Pfizer: Unrestricted research grant, Eli-Lilly: Unrestricted research grant, Consultant of: Sanofi, AB2BIO, Abbvie, Pfizer, MSD, Speakers bureau: Sanofi, Pfizer, Roche, Thermo Fisher Scientific
7
Hézode, Christophe, Michael W. Fried, Massimo Colombo, et al. "Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study." Blood 128, no. 22 (2016): 1303. http://dx.doi.org/10.1182/blood.v128.22.1303.1303.
Full textAbstract:
Abstract Background: Complications from chronic hepatitis C virus (HCV) infection are a major cause of morbidity and mortality among individuals with inherited blood disorders (IBLD). Inability to tolerate ribavirin and frequent comorbidities have limited HCV treatment options in these patients. The aim of the C-EDGE IBLD study was to evaluate the efficacy and safety of a once-daily, fixed-dose combination of elbasvir 50 mg (EBR, an NS5A inhibitor) and grazoprevir 100 mg (GZR, an NS3/4A protease inhibitor) in patients with HCV infection and IBLD, including those with hemoglobinopathies. Methods: C-EDGE-IBLD was a randomized, double-blind, placebo-controlled study of treatment-naïve and treatment-experienced patients with HCV genotype (GT)1, 4, or 6 infection and IBLD (hemophilia A/B, von Willebrand disease, β-thalassemia, or sickle cell anemia). Patients were randomized in a 2:1 ratio to an immediate-treatment group (ITG; 12 weeks of EBR/GZR) or deferred-treatment group (DTG; 12 weeks of placebo, followed by EBR/GZR for 12 weeks). Randomization was stratified according to the presence of cirrhosis and IBLD diagnosis. The primary endpoints were the proportion of patients in the ITG who achieved sustained virologic response (SVR12, HCV RNA <15 IU/mL 12 weeks after completion of treatment) and a comparison of safety and tolerability between patients receiving EBR/GZR in the ITG vs those receiving placebo in the DTG. Results: One hundred fifty-nine patients were randomized (ITG, n = 107; DTG, n = 52). Three patients in the DTG did not commence deferred active treatment; therefore, 156 patients received ≥1 dose of EBR/GZR. Mean age was 44 years. Other baseline patient demographics were as follows: 75% male; 18% black; 41% GT1a-infected; 46% GT1b-infected; 11% GT4-infected; 24% cirrhotic; 6% HIV/HCV co-infected; 43% with hemophilia A/B or von Willebrand disease; 38% with β-thalassemia; 18% with sickle cell anemia. SVR12 was achieved by 92.9% (145/156) of patients receiving EBR/GZR (ITG 93.5% [100/107]; DTG 91.8% [45/49]). Of the 11 patients who did not achieve SVR12, 2 discontinued treatment for reasons unrelated to study medication and 9 relapsed, including 7 who had NS5A resistance-associated variants present at baseline. One patient achieved SVR12 but relapsed between follow-up weeks 12 and 24. SVR12 was achieved by 90.8% (59/65), 95.7% (67/70), and 94.4% (17/18) of patients with HCV GT1a, GT1b, and GT4 infection, respectively (2 patients with GT1 non-a,b achieved SVR and the 1 patient with GT6 infection relapsed). SVR 12 was achieved by 96.3% (26/27) of patients with sickle cell anemia, 95% (57/60) with β-thalassemia, and 89.9% (62/69) with hemophilia A/B or von Willebrand disease. During the initial treatment period (EBR/GZR vs placebo), serious adverse events were reported in 3 (2.9%) patients in the ITG (1 drug-related, 2 related to IBLD) and 6 (11.5%) patients receiving placebo in the DTG (1 drug-related, 3 related to IBLD). In the DTG placebo phase, 1 patient discontinued treatment due to an adverse event and 1 patient withdrew consent. No patient in either arm discontinued treatment due to worsening of underlying IBLD. There was 1 hepatic event of clinical interest in each arm (ALT >3× baseline and >100 U/L). In the EBR/GZR treatment phase of the DTG (n = 49), 3 patients reported serious adverse events; none were drug-related and 2 were related to IBLD. Conclusions: Final data from the C-EDGE IBLD study indicate that EBR/GZR is well tolerated and effective in patients with HCV GT1 or 4 infection with IBLD. Disclosures Hézode: BMS: Consultancy; Janssen: Consultancy; MSD: Consultancy; AbbVie: Consultancy; Gilead: Consultancy. Fried:NIH: Research Funding; Gilead: Consultancy, Research Funding; TARGET PharmaSolutions: Equity Ownership; Merck: Consultancy, Research Funding; BMS: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding. Colombo:Merck: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Science: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Tibotec: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Vertex: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Achillion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Lundbeck: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GenSpera: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AlfaWasserman: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jennerex: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Intercept: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Bourlière:MSD: Consultancy; AbbVie: Consultancy; Gilead: Consultancy; Janssen: Consultancy; GSK: Consultancy; BMS: Consultancy. Ben-Ari:Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Strasser:MSD/Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Norgine: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Honoraria. Perumalswami:Merck: Research Funding; Gilead: Research Funding. Zamor:Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Merck: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Lee:Eli Lilly: Consultancy; BMS: Research Funding; Gilead: Research Funding; Sanofi: Consultancy; Merck: Research Funding; Novartis: Consultancy. Satoskar:Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Research Funding. Sherman:AbbVie: Research Funding; Gilead: Research Funding; BMS: Research Funding; Merck: Consultancy, Research Funding. Morgan:Merck & Co., Inc.: Employment, Equity Ownership. Qiu:Merck: Employment. Hwang:Merck: Employment, Equity Ownership. Robertson:Merck: Employment, Equity Ownership. Nguyen:Merck: Employment. Barr:Merck: Employment, Equity Ownership. Wahl:Merck: Employment. Haber:Merck: Employment. Chase:Merck: Employment. Talwani:Merck & Co., Inc: Employment. Di Marco:Gilead: Research Funding.
8
Nugroho, Sidiq Permono, and Syamsudin Syamsudin. "PENGUKURAN INDEKS KEPUASAN PENGGUNA DATA TERHADAP PELAYANAN PADA BADAN PUSAT STATISTIK KOTA SURAKARTA." Benefit: Jurnal Manajemen dan Bisnis 1, no. 1 (2016): 57. http://dx.doi.org/10.23917/benefit.v1i1.2366.
Full textAbstract:
This research aims was to figure out user’s satisfaction index towards this public service toward Central Bureau of Statistics (BPS). BPS is a non-ministry government institution implements the bureaucracy reform, and provides comprehensive, accurate, and sophisticated statistics in order to create a System of National Statistics. The data analysis technique for this research is Users (people who once used The Central Bureau of Statistic Service) Satisfaction Index, counted through weighted average values of some service elements based on Number 63/KEP/M.PAN/7/2003. Among the 120 users of The Central Bureau of Statistics, this research shows that The Satisfaction Index reaches 75.31 (good), but it still need to be improved remember there are some indicators showing a not quite good Performance Index. Totally 20 out of 24 indicators are categorized into ‘good service’, while the other fours indicator need to be enhanced and improved.
9
Shah, Gaurav, Fady M. Mikhail, Harry P. Erba, and Nikolaos Papadantonakis. "Omission of Maintenance in Patients with High-Risk Acute Promyelocytic Leukemia (APL) in the Era of ATRA/Arsenic Consolidation." Blood 132, Supplement 1 (2018): 5192. http://dx.doi.org/10.1182/blood-2018-99-114872.
Full textAbstract:
Abstract Introduction: The role of maintenance treatment in patients with high-risk Acute Promyelocytic Leukemia (APL) in the era of ATO/ATRA is unclear. Methods: We retrospectively reviewed electronic medical records of patients with high-risk Acute Promyelocytic Leukemia (APL) and identified patients who did not receive maintenance. Results: We have identified 9 patients with high-risk APL who did not receive maintenance therapy. Five patients were females and 8 were white. The median age was 47-year-old (range 26-77 year old). The median WBC was 41,500 (range 14,700-167,500). The median blast percentage was 81% (range 1%-91%). The median platelet count was 28,000 (range 7,000-60,000). One patient received G-CSF prior to diagnosis of APL but the majority of cells on presentation were blasts. Two patients had additional cytogenetics changes apart from presence of t(15;17)(q22;21). Three patients had FLT3 ITD detected. All patients received ATRA during induction. Moreover, during induction 8 patients received Arsenic and all but one received Idarubicin. Seven of the 8 received Idarubicin according to Australasian APLM4 study. Bone marrow biopsies following induction were negative for PML/RARA by FISH analysis. RT-PCR for PML/ RARA was obtained at the time of the bone marrow (BM) biopsy in 8 patients and was negative. One patient had assessment close to the time of BM biopsy from peripheral blood and was negative. The median time from diagnosis to post Induction bone marrow was 49 days (range 32-56 days). All patients received 4 cycle of consolidation with ATRA and ATO according to Italian-German APL 0406 trial ( Lo-Coco et al., NEJM 2013). Three patients received Intrathecal chemotherapy for prophylaxis. Six of 9 had end-of-treatment bone marrow, which were negative for relapse. All patients were subsequently followed by RT-PCR for PML/RARA for molecular relapse. At last follow-up, all patients are alive and were in molecular remission. The median follow-up from diagnosis was 916 day (range 429-1674). Conclusion: We report our experience of high-risk APL patients in our institution who did not receive maintenance. None of the patients relapsed and our data suggest that patients that do not undergo maintenance in the era of ATO/Arsenic consolidation may remain in remission. Table. Table. Disclosures Erba: Takeda/Millenium: Research Funding; Pfizer: Consultancy, Other: grant; Celgene: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Takeda/Millenium: Research Funding; Pfizer: Consultancy, Other: grant; Incyte: Consultancy, Speakers Bureau; Amgen: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Astellas: Research Funding; Incyte: Consultancy, Speakers Bureau; Jazz: Consultancy, Speakers Bureau; Astellas: Research Funding; Seattle Genetics: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Amgen: Research Funding; Novartis: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Astellas: Research Funding; Agios: Consultancy, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Glycomimetics: Consultancy, Other: Chair, Data and Safety Monitoring Committee; Novartis: Consultancy, Speakers Bureau; Amgen: Research Funding; Amgen: Research Funding; Glycomimetics: Consultancy, Other: Chair, Data and Safety Monitoring Committee; Astellas: Research Funding; Seattle Genetics: Consultancy, Research Funding; Janssen: Research Funding; Janssen: Research Funding; MacroGenics: Consultancy; MacroGenics: Consultancy; Pfizer: Consultancy, Other: grant; Juno: Research Funding; Juno: Research Funding; Pfizer: Consultancy, Other: grant; Agios: Consultancy, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Seattle Genetics: Consultancy, Research Funding; Incyte: Consultancy, Speakers Bureau; Seattle Genetics: Consultancy, Research Funding; Incyte: Consultancy, Speakers Bureau; Jazz: Consultancy, Speakers Bureau; Takeda/Millenium: Research Funding; Immunogen: Consultancy, Research Funding; Jazz: Consultancy, Speakers Bureau; Takeda/Millenium: Research Funding; Celgene: Consultancy, Speakers Bureau; Immunogen: Consultancy, Research Funding; MacroGenics: Consultancy; Glycomimetics: Consultancy, Other: Chair, Data and Safety Monitoring Committee; MacroGenics: Consultancy; Celgene: Consultancy, Speakers Bureau; Juno: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Glycomimetics: Consultancy, Other: Chair, Data and Safety Monitoring Committee; Juno: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Immunogen: Consultancy, Research Funding; Jazz: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Immunogen: Consultancy, Research Funding. Papadantonakis:Agios pharmaceuticals: Honoraria, Other: advisory board.
10
Tsakiris, Dimitrios A., Johannes Oldenburg, Robert Klamroth, et al. "Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies." Blood 136, Supplement 1 (2020): 1. http://dx.doi.org/10.1182/blood-2020-139873.
Full textAbstract:
Introduction: Long-term effectiveness and safety data in patients treated in routine clinical practice settings can be captured from real-world studies. The international (INT) and German (GER) Antihemophilic factor (recombinant; rAHF) Hemophilia A (HA) outcome Database (AHEAD) studies assess long-term effectiveness and safety outcomes in patients with moderate HA (factor VIII level 1-5%) or severe HA (factor VIII &lt;1%) receiving rAHF (ADVATE®; Baxalta US Inc., a Takeda company, Lexington, MA, USA) in routine clinical practice. Methods: These are non-interventional, prospective, long-term, multicenter studies (INT: NCT02078427; GER: DRKS 00000556). Key outcomes include Gilbert scores (primary endpoint; pain scored 0-3; bleeding scored 0-3, and physical exam scored 0-12), annualized bleeding rates (ABRs) by disease severity, and adverse events (AEs). Findings reported here are from the 6-year interim analysis (data cut-off: July 15, 2019), and focus on patients who have received rAHF prophylaxis or on-demand (OD) treatment for ≥5 years in the studies. All data are reported for the safety analysis set (SAS), which comprised patients who passed screening and were assigned to a treatment group or regimen in the INT study, or were enrolled and have received ≥1 dose of rAHF since study enrollment in the GER study. Results: At the time of analysis, the INT study SAS comprised 707 patients, 156 of whom had received ≥5 years of rAHF treatment during the study. The GER study SAS comprised 382 patients, 231 of whom had received ≥5 years of rAHF treatment. Average Gilbert scores (all joints) were consistently low (years 1-6: median 0-1.0; mean 0-1.3) for both children aged 2 to &lt;12 years and adolescents aged 12 to &lt;18 years receiving rAHF prophylaxis within both studies. In the INT study, average Gilbert scores were lower with prophylaxis than with OD therapy in adults (aged ≥18 years) throughout the observation period (years 1-6: median: 0.9-1.4 [n=8-25] vs 1.4-6.3 [n=2-8], respectively; mean: 1.4-2.2 vs 2.1-6.3; respectively); significant differences (P&lt;0.05) between mean values were observed for years 3, 4, and 6. In the GER study, average Gilbert scores were slightly higher with prophylaxis than with OD in adults (years 1-6: median: 0.7-2.2 [n=12-37] vs 0.3-1.4 [n=2-15], respectively; mean: 1.0-2.7 vs 0.5-2.2, respectively; P-values not available). In the INT study, ABRs were consistently lower in patients receiving rAHF prophylaxis than in those receiving rAHF OD, irrespective of disease severity (Table). A similar trend was observed in the GER study in patients with severe HA, whereas ABRs were similar for both treatment regimens in patients with moderate HA. In both studies, greater proportions of patients with moderate or severe HA receiving rAHF prophylaxis had 0 bleeds than those receiving rAHF OD (Table). In the INT study, 842 AEs were reported in 116/156 (74.4%) patients, including 2 treatment-related serious AEs in 2 (1.3%) patients. In the GER study, 1321 AEs were reported in 197/231 (85.3%) patients, including 29 treatment-related serious AEs in 14 (6.1%) patients. Conclusions: These findings in patients receiving rAHF for ≥5 years in a real-world setting corroborate previous data on the long-term efficacy and tolerability of rAHF in patients with moderate or severe HA. rAHF demonstrated effectiveness in maintaining joint health (as measured by Gilbert scores) in adult patients. Table Disclosures Tsakiris: Roche: Research Funding; Shire, a Takeda company: Research Funding; Sobi: Research Funding; Bayer: Research Funding; CSL Behring: Research Funding; Novo Nordisk: Research Funding; Pfizer: Research Funding; Octapharma: Research Funding. Oldenburg:Sobi: Consultancy, Speakers Bureau; Bayer: Consultancy, Research Funding, Speakers Bureau; Biotest: Consultancy, Research Funding, Speakers Bureau; CSL Behring: Consultancy, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Octapharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Shire, a Takeda company: Consultancy, Research Funding, Speakers Bureau; Biogen: Consultancy, Speakers Bureau; Chugai: Consultancy, Speakers Bureau; Grifols: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau. Klamroth:Pfizer: Consultancy, Research Funding, Speakers Bureau; Biotest: Speakers Bureau; Grifols: Speakers Bureau; Takeda/Shire: Consultancy, Research Funding, Speakers Bureau; Octapharma: Consultancy, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Biomarin: Consultancy, Research Funding, Speakers Bureau; CSL Behring: Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Bayer: Consultancy, Research Funding, Speakers Bureau. Guillet:CSL Behring: Research Funding, Speakers Bureau; Octapharma: Research Funding; Bayer: Consultancy; Novo Nordisk: Consultancy, Speakers Bureau; Shire, a Takeda company: Consultancy, Speakers Bureau; Roche-Chugai: Consultancy, Speakers Bureau. Khair:Shire, a Takeda company: Consultancy, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Pfizer: Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Sobi: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy, Speakers Bureau; Baxalta/Shire, Takeda companies: Research Funding. Huth-Kühne:Bayer: Consultancy; CSL Behring: Consultancy; Shire, a Takeda company: Consultancy; Sobi: Consultancy. Kurnik:Sobi: Consultancy, Research Funding; Biotest: Consultancy, Speakers Bureau; Bayer: Consultancy, Research Funding, Speakers Bureau; CSL Behring: Consultancy, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Pfizer: Research Funding; Roche: Consultancy, Research Funding, Speakers Bureau; Shire, a Takeda company: Consultancy, Research Funding, Speakers Bureau. Regensburger:Takeda Pharma Vertrieb GmbH & Co. KG: Current Employment, Current equity holder in publicly-traded company. Botha:Takeda Pharmaceutical International AG: Current Employment, Current equity holder in publicly-traded company. Fernandez:Takeda Pharmaceutical International AG: Current Employment, Current equity holder in publicly-traded company. Tang:Takeda Pharmaceutical International AG: Current Employment, Current equity holder in publicly-traded company. Ozelo:Pfizer: Consultancy, Research Funding; Shire/Takeda: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Research Funding, Speakers Bureau; Bioverativ/Sanofi: Consultancy, Research Funding; BioMarin: Consultancy, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau.
Dissertations / Theses on the topic "Bureau of Data and Research"
1
Scott, Mark. "Research data management." Thesis, University of Southampton, 2014. https://eprints.soton.ac.uk/374711/.
Full textAbstract:
Scientists within the materials engineering community produce a wide variety of data, ranging from large 3D volume densitometry files (voxel) generated by microfocus computer tomography (μCT) to simple text files containing results from tensile tests. Increasingly they need to share this data as part of international collaborations. The design of a suitable database schema and the architecture of a flexible system that can cope with the varying information is a continuing problem in the management of heterogeneous data. We discuss the issues with managing such varying data, and present a model flexible enough to meet users’ diverse requirements. Metadata is held using a database and its design allows users to control their own data structures. Data is held in a file store which, in combination with the metadata, gives huge flexibility and means the model is limited only by the file system. Using examples from materials engineering and medicine we illustrate how the model can be applied. We will also discuss how this data model can be used to support an institutional document repository, showing how data can be published in a remote data repository at the same time as a publication is deposited in a document repository. Finally, we present educational material used to introduce the concepts of research data management. Educating students about the challenges and opportunities of data management is a key part of the solution and helps the researchers of the future to start to think about the relevant issues early on in their careers. We have compiled a set of case studies to show the similarities and differences in data between disciplines, and produced documentation for students containing the case studies and an introduction to the data lifecycle and other data management practices. Managing in-use data and metadata is just as important to users as published data. Appropriate education of users and a data staging repository with a flexible and extensible data model supports this without precluding the ability to publish the data at a later date.
2
Kamenieva, Iryna. "Research Ontology Data Models for Data and Metadata Exchange Repository." Thesis, Växjö University, School of Mathematics and Systems Engineering, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:vxu:diva-6351.
Full textAbstract:
<p>For researches in the field of the data mining and machine learning the necessary condition is an availability of various input data set. Now researchers create the databases of such sets. Examples of the following systems are: The UCI Machine Learning Repository, Data Envelopment Analysis Dataset Repository, XMLData Repository, Frequent Itemset Mining Dataset Repository. Along with above specified statistical repositories, the whole pleiad from simple filestores to specialized repositories can be used by researchers during solution of applied tasks, researches of own algorithms and scientific problems. It would seem, a single complexity for the user will be search and direct understanding of structure of so separated storages of the information. However detailed research of such repositories leads us to comprehension of deeper problems existing in usage of data. In particular a complete mismatch and rigidity of data files structure with SDMX - Statistical Data and Metadata Exchange - standard and structure used by many European organizations, impossibility of preliminary data origination to the concrete applied task, lack of data usage history for those or other scientific and applied tasks.</p><p>Now there are lots of methods of data miming, as well as quantities of data stored in various repositories. In repositories there are no methods of DM (data miming) and moreover, methods are not linked to application areas. An essential problem is subject domain link (problem domain), methods of DM and datasets for an appropriate method. Therefore in this work we consider the building problem of ontological models of DM methods, interaction description of methods of data corresponding to them from repositories and intelligent agents allowing the statistical repository user to choose the appropriate method and data corresponding to the solved task. In this work the system structure is offered, the intelligent search agent on ontological model of DM methods considering the personal inquiries of the user is realized.</p><p>For implementation of an intelligent data and metadata exchange repository the agent oriented approach has been selected. The model uses the service oriented architecture. Here is used the cross platform programming language Java, multi-agent platform Jadex, database server Oracle Spatial 10g, and also the development environment for ontological models - Protégé Version 3.4.</p>
3
Van, Wyk Barend Johannes. "The relationship between Research Data Management and Virtual Research Environments." Thesis, University of Pretoria, 2018. http://hdl.handle.net/2263/64292.
Full textAbstract:
The aim of the study was to compile a conceptual model of a Virtual Research Environment (VRE) that indicates the relationship between Research Data Management (RDM) and VREs. The outcome of this study was that VREs are ideal platforms for the management of research data.
In the first part of the study, a literature review was conducted by focusing on four themes: VREs and other concepts related to VREs; VRE components and tools; RDM; and the relationship between VREs and RDM. The first theme included a discussion of definitions of concepts, approaches to VREs, their development, aims, characteristics, similarities and differences of concepts, an overview of the e-Research approaches followed in this study, as well as an overview of concepts used in this study. The second theme consisted of an overview of developments of VREs in four countries (United Kingdom, USA, The Netherlands, and Germany), an indication of the differences and similarities of these programmes, and a discussion on the concept of research lifecycles, as well as VRE components. These components were then matched with possible tools, as well as to research lifecycle stages, which led to the development of a first conceptual VRE framework. The third theme included an overview of the definitions of the concepts ‘data’ and ‘research data’, as well as RDM and related concepts, an investigation of international developments with regards to RDM, an overview of the differences and similarities of approaches followed internationally, and a discussion of RDM developments in South Africa. This was followed by a discussion of the concept ‘research data lifecycles’, their various stages, corresponding processes and the roles various stakeholders can play in each stage. The fourth theme consisted of a discussion of the relationship between research lifecycles and research data lifecycles, a discussion on the role of RDM as a component within a VRE, the management of research data by means of a VRE, as well as the presentation of a possible conceptual model for the management of research data by means of a VRE. This literature review was conducted as a background and basis for this study.
In the second part of the study, the research methodology was outlined. The chosen methodology entailed a non-empirical part consisting of a literature study, and an empirical part consisting of two case studies from a South African University. The two case studies were specifically chosen because each used different methods in conducting research. The one case study used natural science oriented data and laboratory/experimental methods, and the other, human orientated data and survey instruments. The proposed conceptual model derived from the literature study was assessed through these case studies and feedback received was used to modify and/or enhance the conceptual model.
The contribution of this study lies primarily in the presentation of a conceptual VRE model with distinct component layers and generic components, which can be used as technological and collaborative frameworks for the successful management of research data.<br>Thesis (DPhil)--University of Pretoria, 2018.<br>National Research Foundation<br>Information Science<br>DPhil<br>Unrestricted
4
Lynch, Kevin John. "Data manipulation in collaborative research systems." Diss., The University of Arizona, 1989. http://hdl.handle.net/10150/184923.
Full textAbstract:
This dissertation addresses data manipulation in collaborative research systems, including what data should be stored, the operations to be performed on that data, and a programming interface to effect this manipulation. Collaborative research systems are discussed, and requirements for next-generation systems are specified, incorporating a range of emerging technologies including multimedia storage and presentation, expert systems, and object-oriented database management systems. A detailed description of a generic query processor constructed specifically for one collaborative research system is given, and its applicability to next-generation systems and emerging technologies is examined. Chapter 1 discusses the Arizona Analyst Information System (AAIS), a successful collaborative research system being used at the University of Arizona and elsewhere. Chapter 2 describes the generic query processing approach used in the AAIS, as an efficient, nonprocedural, high-level programmer interface to databases. Chapter 3 specifies requirements for next-generation collaborative research systems that encompass the entire research cycle for groups of individuals working on related topics over time. These requirements are being used to build a next-generation collaborative research system at the University of Arizona called CARAT, for Computer Assisted Research and Analysis Tool. Chapter 4 addresses the underlying data management systems in terms of the requirements specified in Chapter 3. Chapter 5 revisits the generic query processing approach used in the AAIS, in light of the requirements of Chapter 3, and the range of data management solutions described in Chapter 4. Chapter 5 demonstrates the generic query processing approach as a viable one, for both the requirements of Chapter 3 and the DBMSs of Chapter 4. The significance of this research takes several forms. First, Chapters 1 and 3 provide detailed views of a current collaborative research system, and of a set of requirements for next-generation systems based on years of experience both using and building the AAIS. Second, the generic query processor described in Chapters 2 and 5 is shown to be an effective, portable programming language to database interface, ranging across the set of requirements for collaborative research systems as well as a number of underlying data management solutions.
5
Spinuso, Alessandro. "Active provenance for data intensive research." Thesis, University of Edinburgh, 2018. http://hdl.handle.net/1842/33181.
Full textAbstract:
The role of provenance information in data-intensive research is a significant topic of discussion among technical experts and scientists. Typical use cases addressing traceability, versioning and reproducibility of the research findings are extended with more interactive scenarios in support, for instance, of computational steering and results management. In this thesis we investigate the impact that lineage records can have on the early phases of the analysis, for instance performed through near-real-time systems and Virtual Research Environments (VREs) tailored to the requirements of a specific community. By positioning provenance at the centre of the computational research cycle, we highlight the importance of having mechanisms at the data-scientists' side that, by integrating with the abstractions offered by the processing technologies, such as scientific workflows and data-intensive tools, facilitate the experts' contribution to the lineage at runtime. Ultimately, by encouraging tuning and use of provenance for rapid feedback, the thesis aims at improving the synergy between different user groups to increase productivity and understanding of their processes. We present a model of provenance, called S-PROV, that uses and further extends PROV and ProvONE. The relationships and properties characterising the workflow's abstractions and their concrete executions are re-elaborated to include aspects related to delegation, distribution and steering of stateful streaming operators. The model is supported by the Active framework for tuneable and actionable lineage ensuring the user's engagement by fostering rapid exploitation. Here, concepts such as provenance types, configuration and explicit state management allow users to capture complex provenance scenarios and activate selective controls based on domain and user-defined metadata. We outline how the traces are recorded in a new comprehensive system, called S-ProvFlow, enabling different classes of consumers to explore the provenance data with services and tools for monitoring, in-depth validation and comprehensive visual-analytics. The work of this thesis will be discussed in the context of an existing computational framework and the experience matured in implementing provenance-aware tools for seismology and climate VREs. It will continue to evolve through newly funded projects, thereby providing generic and user-centred solutions for data-intensive research.
6
Tam, Wan Ting (Winnie). "Discipline and research data in geography." Thesis, Loughborough University, 2016. https://dspace.lboro.ac.uk/2134/26997.
Full textAbstract:
Research data is essential to scholarship. The value of research data and its management has been increasingly recognized by policy makers and higher education institutions. A deep understanding of disciplinary practices is vital to develop culturally-sensitive policy, tools and services for successful data management. Previous research has shown that data practices vary across sub-fields and disciplines. However, much less is known about how disciplinary cultures shape data practices. There is a need to theorise research data practices based on empirical evidence in order to inform policy, tools and services. The aim of the thesis is to examine the interrelation between data practices and disciplinary cultures within geography. Geography is well-established and multidisciplinary, consisting of elements from the sciences, social sciences and humanities. By examining a single discipline this thesis develops a theoretical understanding of research data practices at a finer level of granularity than would be achieved by looking at broad disciplinary groupings such as the physical and social sciences. Data collection and analysis consisted of two phases. Phase one was exploratory, including an analysis of geography department websites and researcher web profiles and a bibliometric study of collaboration patterns based on co-authorship. Phase one aimed to understand the disciplinary characteristics of geography in preparation for Phase two. The second phase consisted of a series of 23 semi-structured interviews with researchers in geography, which aimed to understand researchers data practices and their attitudes toward data sharing within the context of the sub-discipline(s) they inhabited. The findings of the thesis show that there are contrasting intellectual, social and data differences between physical and human geography. For example, intellectually, these two branches of geography differ in terms of their research objects and methods; socially, they differ in terms of the scale of their collaborative activities and the motivations to collaborate; furthermore, the nature of data, how data is collected and data sharing practices are also different between physical and human geography. The thesis concludes that differences in the notion of data and data sharing practices are grounded in disciplinary characteristics. The thesis develops a new three-dimensional framework to better understand the notion of data from a disciplinary perspective. The three dimensions are (1) physical form, (2) intellectual content and (3) social construction. Furthermore, Becher and Trowler s (2001) disciplinary taxonomy i.e. hard-soft/pure-applied, and the concepts urban-rural ways of life and convergent-divergent communities, is shown to be useful to explain the diverse data sharing practices of geographers. The thesis demonstrates the usefulness of applying disciplinary theories to the sphere of research data management.
7
Scott, Kimberly M. Ph D. Massachusetts Institute of Technology. "Online data collection for developmental research." Thesis, Massachusetts Institute of Technology, 2018. https://hdl.handle.net/1721.1/127709.
Full textAbstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, 2018<br>Cataloged from PDF version of thesis. Page 140 blank.<br>Includes bibliographical references (pages 134-139).<br>The strategies infants and young children use to understand the world around them provide unique insight into the structure of human cognition. However, developmental research is subject to heavy pragmatic constraints on recruiting large numbers of participants, bringing families back for repeat sessions, and working with special populations or diverse samples. These constraints limit the types of questions that can be addressed in the lab as well as the quality of evidence that can be obtained. In this dissertation, I present a new platform, "Lookit," that allows researchers to conduct developmental experiments online via asynchronous webcam-recorded sessions, with the aim of expanding the set of questions that we can effectively answer. I first present the results of a series of empirical studies conducted in the laboratory to assess difficulty faced by infants in integrating information across visual hemifields (Chapter 2), as an illustration of the creative workarounds in study design necessary to accommodate the difficulty of participant recruitment. The rest of this work concerns the development of the online platform, from designing the prototype (Chapter 3) and initial proof-of-concept studies (Chapter 4) to the demonstration of an interface for researchers to specify and manage their studies on a collaborative platform (Chapter 5). I show that we are able to reliably collect and code dependent measures including looking times, preferential looking, and verbal responses on Lookit; to work with more representative samples than in the lab; and to flexibly implement a wide variety of study designs of interest to developmental researchers.<br>by Kimberly M. Scott.<br>Ph. D.<br>Ph.D. Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences
8
Bjarnadóttir, Margrét Vilborg. "Data-driven approach to health care : applications using claims data." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/45946.
Full textAbstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Sloan School of Management, Operations Research Center, 2008.<br>Includes bibliographical references (p. 123-130).<br>Large population health insurance claims databases together with operations research and data mining methods have the potential of significantly impacting health care management. In this thesis we research how claims data can be utilized in three important areas of health care and medicine and apply our methods to a real claims database containing information of over two million health plan members. First, we develop forecasting models for health care costs that outperform previous results. Secondly, through examples we demonstrate how large-scale databases and advanced clustering algorithms can lead to discovery of medical knowledge. Lastly, we build a mathematical framework for a real-time drug surveillance system, and demonstrate with real data that side effects can be discovered faster than with the current post-marketing surveillance system.<br>by Margrét Vilborg Bjarnadóttir.<br>Ph.D.
9
Patterton, Louise Hilda. "Research data management practices of emerging researchers at a South African research council." Diss., University of Pretoria, 2016. http://hdl.handle.net/2263/59502.
Full textAbstract:
Management of research data is globally being seen as part of good research practice. As a result of this, funders are increasingly insisting on proof of good research data management (RDM) practices when funding proposals are submitted. This study aimed at establishing the data management practices of emerging researchers at the Council for Scientific and Industrial Research (CSIR), South Africa. With no official RDM procedures currently being implemented at the CSIR, it was hoped that by gaining information about the RDM practices of emerging CSIR researchers, as well as insight into the RDM challenges experienced by them, this researcher would be able to put forward recommendations enabling the establishing of an RDM regime at the CSIR.
The study aimed at answering several research questions. The main research question was:
How can an organisation like the CSIR ensure that future researchers apply best practices when managing the CSIR’s research data?
Five research sub-questions were identified:
1. What are the international RDM requirements, standards, best practices and expectations that are being developed?
2. What data practices need more formalised support: at CSIR, nationally, internationally?
3. What data are collected and held by emerging researchers in the CSIR?
4. What are the current RDM practices and themes among emerging researchers in the CSIR?
5. What are the RDM-related challenges, issues and concerns facing emerging researchers at the CSIR?
A total of 48 emerging researchers from the Council for Scientific and Industrial Research (CSIR), South Africa completed an online survey investigating their RDM practices. RDM practices investigated included the use of data management plans, data storage and backup locations, creation of metadata, metadata standard adherence, and data sharing practices. Challenges faced when managing research data, as well as RDM needs and requirements, also formed part of the survey. Results of the online questionnaire revealed that the RDM practices of the group studied do not show to differ significantly from experienced CSIR researchers, or from researchers studied elsewhere on the globe. Findings enabled this researcher to put forward several recommendations which would assist in the implementing of a formalised RDM structure at the CSIR. Recommendations addressed, but were not limited to: formalization of RDM procedures, RDM marketing, and RDM training.<br>Dissertation (MIS)--University of Pretoria, 2016.<br>Information Science<br>MIS<br>Unrestricted
10
Le, Guen Thibault. "Data-driven pricing." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/45627.
Full textAbstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, Operations Research Center, 2008.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Includes bibliographical references (p. 143-146).<br>In this thesis, we develop a pricing strategy that enables a firm to learn the behavior of its customers as well as optimize its profit in a monopolistic setting. The single product case as well as the multi product case are considered under different parametric forms of demand, whose parameters are unknown to the manager. For the linear demand case in the single product setting, our main contribution is an algorithm that guarantees almost sure convergence of the estimated demand parameters to the true parameters. Moreover, the pricing strategy is also asymptotically optimal. Simulations are run to study the sensitivity to different parameters.Using our results on the single product case, we extend the approach to the multi product case with linear demand. The pricing strategy we introduce is easy to implement and guarantees not only learning of the demand parameters but also maximization of the profit. Finally, other parametric forms of the demand are considered. A heuristic that can be used for many parametric forms of the demand is introduced, and is shown to have good performance in practice.<br>by Thibault Le Guen.<br>S.M.
Books on the topic "Bureau of Data and Research"
1
Feenberg, Daniel. Improving the accessibility of the NBER's historical data. National Bureau of Economic Research, 1995.
Find full text
2
Cunningham, Diane. Data bases available at the National Bureau of Standards Research Information Center. 5th ed. U.S. Dept. of Commerce, National Bureau of Standards, 1986.
Find full text
3
Office, General Accounting. 2000 census: Coverage evaluation interviewing overcame challenges, but further research needed : report to congressional requesters. GAO, 2001.
Find full text
4
United States. Bureau of Reclamation. Denver Office. Research and Laboratory Services Division. Bureau of Reclamation research. Dept. of the Interior, Research and Laboratory Services Division, 1992.
Find full text
5
Office, United States Department of the Interior Bureau of Land Management ALMRS Project. Bureau of Land Management data integration. Bureau of Land Management, ALMRS Project Office, 1985.
Find full text
6
Subcommittee, United States Congress House Committee on Government Operaions Legislation and National Security. Computer Security Research and Training Act of 1985: Hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, first session, on H.R. 2889 ... September 18, 1985. U.S. G.P.O., 1986.
Find full text
8
Comba, P. G. Bureau of Mines cyanide research. American Institute of Mining, Metallurgical, and Petroleum Engineers, 1993.
Find full text
9
United States. Bureau of the Census. Data User Services Division., ed. CENDATA, the Census Bureau online. U.S. Dept. of Commerce, Economics and Statistics Administration, Bureau of the Census, 1991.
Find full textBook chapters on the topic "Bureau of Data and Research"
1
Simon, Stephen D. "Census Bureau (U.S.)." In Encyclopedia of Big Data. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-32001-4_257-1.
Full text
2
Rukmana, Deden, and Dinar Ramadhani. "Income Inequality and Socioeconomic Segregation in Jakarta." In The Urban Book Series. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64569-4_7.
Full textAbstract:
AbstractSocioeconomic segregation has become a common phenomenon, both in the Global North and Global South, and highly relates to income inequality. The merging of these two notions affects the geography of residential areas which are based on the socio-occupational composition. This chapter focuses on the Jakarta Metropolitan Area (JMA). Not only is Jakarta the largest metropolitan area in Southeast Asia, it is also one of the most dynamic. Batavia, the colonial capital of the former Dutch East Indies in the first half of the twentieth century, was a small urban area of approximately 150,000 residents. In the second half of the century, Batavia became Jakarta, a megacity of 31 million people and the capital of independent Indonesia was beset with most of the same urban problems experienced in twenty-first-century Southeast Asia, including poverty, income inequality, and socioeconomic segregation. This study aims to identify the correlation among income inequality, socioeconomic segregation, and other institutional and contextual factors which caused residential segregation in JMA. The analysis consists of two stages. First, we examine income inequality measured by the Gini Index as well as the occupational structure based on the International Standard Classification of Occupations (ISCO). Second, we investigate residential segregation by using the Dissimilarity Index as a result of socioeconomic intermixing in residential areas. The data in this study comes from multiple sources including Indonesia’s Central Bureau of Statistics, Indonesia’s National Socio-economic Survey (Susenas), Indonesia’s Economic Census, Jakarta’s Regional Bureau of Statistics, and policies related to the housing system and investment in the JMA. This study also produces maps of socioeconomic segregation patterns from several sources including Jakarta’s Geospatial Information Centre, Jakarta’s Spatial Plan Information System, and the Indonesian Poverty Map by the SMERU Research Institute.
3
Rutherford, Malcolm. "National Bureau of Economic Research." In The New Palgrave Dictionary of Economics. Palgrave Macmillan UK, 2008. http://dx.doi.org/10.1057/978-1-349-95121-5_2073-1.
Full text
4
Rutherford, Malcolm. "National Bureau of Economic Research." In The New Palgrave Dictionary of Economics. Palgrave Macmillan UK, 2018. http://dx.doi.org/10.1057/978-1-349-95189-5_2073.
Full text
5
Turner, Barry. "National Bureau of Economic Research (NBER)." In The Statesman’s Yearbook. Palgrave Macmillan UK, 2012. http://dx.doi.org/10.1007/978-1-349-59541-9_150.
Full text
6
Turner, Barry. "National Bureau of Economic Research (NBER)." In The Statesman’s Yearbook. Palgrave Macmillan UK, 2011. http://dx.doi.org/10.1007/978-1-349-59051-3_147.
Full text
7
Turner, Barry. "National Bureau of Economic Research (NBER)." In The Statesman’s Yearbook. Palgrave Macmillan UK, 2014. http://dx.doi.org/10.1007/978-1-349-67278-3_155.
Full text
8
Heath-Brown, Nick. "National Bureau of Economic Research (NBER)." In The Stateman’s Yearbook. Palgrave Macmillan UK, 2015. http://dx.doi.org/10.1007/978-1-349-57823-8_156.
Full text
9
Turner, Barry. "National Bureau of Economic Research (NBER)." In The Statesman’s Yearbook. Palgrave Macmillan UK, 2013. http://dx.doi.org/10.1007/978-1-349-59643-0_150.
Full text
10
Bolstad, D. D., J. R. M. Hill, and J. M. Karhnak. "US Bureau of Mines rock bolting research." In Rock Bolting. Routledge, 2021. http://dx.doi.org/10.1201/9780203740507-29.
Full textConference papers on the topic "Bureau of Data and Research"
1
Hwang, Ching-Her, Wen-Ching Lee, Wen-Fang Hsieh, Ching-Piao Tsai, and Hwa Chien. "Statistical Analysis on the Extreme Events of Big Waves Under Wave Climate Change Around Taiwan Waters." In ASME 2011 30th International Conference on Ocean, Offshore and Arctic Engineering. ASMEDC, 2011. http://dx.doi.org/10.1115/omae2011-49896.
Full textAbstract:
This study aimed to analyze the statistical characteristics of wave heights, wave energy and wave steepness, in order to investigate the wave climate changes around Taiwan Waters, especially for extreme events of big waves. The operational observation of Taiwan sea waves was initiated by the Central Weather Bureau in 1998; however, due to insufficient data length and low data space coverage, the data are unable to serve as references for long-term wave climate change research. Hence, this study adopted the SWAN (Simulation of Wave in Nearshore) Numerical Wave Hindcasting Method, which is a common method used in many studies, to hindcast the history of a wave field. The re-analysis on wind field data of the last 60 years (1948∼2008), published by the National Centers for Environmental Prediction (NCEP), was employed to make the wind field grid consistent with the hindcast wave field grid. Moreover, the Typhoon Wind Field Grid Down Scaling technique proposed by Winter & Chiou (2007) was applied to interpolate a U10 analysis field that better fits an actual typhoon wind field. The hindcast wave data were compared and validated with directional spectra, which were observed by the meteorological/oceanographic data buoys set up by the Central Weather Bureau and Water Resources Agency since 1997. Longdong, Hualien and Hsinchu Stations were chosen to represent the wave characteristics of sea areas around the island of Taiwan. According to observation data, model parameters were adjusted so that the hindcast results could be closer to observed data in Taiwan sea areas.
2
Weerakkody, Niranjala. "Where Else Have You Been? The Effects of Diaspora Consciousness and Transcultural Mixtures on Ethnic Identity." In InSITE 2006: Informing Science + IT Education Conference. Informing Science Institute, 2006. http://dx.doi.org/10.28945/3037.
Full textAbstract:
In social science research, the demographic categories of ethnicity are linked to what the census bureau considers as a person’s ethnic heritage. However, these categories are based on the societal assumption that members of a given category share the same characteristics and life experiences, even though the heterogeneity between members within a category may be as diverse as between categories. The paper examines the 15 interview subjects of a research study drawn from 10 minority migrant groups, where seven of them indicated significant transcultural experiences before migrating to Australia. It argues that their lived experiences and subjectivity vary from others who migrated directly from their native countries. The formers’ diaspora consciousness and transcultural mixtures may introduce an artifact to a research study’s design, affecting the validity of the data collected. The paper examines other situations where this anomaly can occur and proposes precautions to minimize its negative effects.
3
Toderan, C., T. Richir, J. D. Caprace, and Ph Rigo. "Ultimate Strength of Stiffened Panels Assesment Taking Into Account Model Uncertainty." In 25th International Conference on Offshore Mechanics and Arctic Engineering. ASMEDC, 2006. http://dx.doi.org/10.1115/omae2006-92426.
Full textAbstract:
This paper presents a methodology to take into account model uncertainties related to the load-end shortening curve of stiffened panels. This method is a part of a research activity carried out at University of Liege. His goal is to propose a reliability based model to assess hull girder ultimate strength using a progressive collapse algorithm. The numerical results presented here concern the load-shortening model chosen for this research, which is based on Bureau Veritas rules. Model uncertainty is quantified as a parameter considered as a random variable. Four statistical moments (mean, standard deviation, skewness and kurtosis) of this parameter are calculated and analyzed using a data-base of stiffened panels test results published in recent years. In order to increase the number of “actual” values for the statistical assessment, the data-base is completed with non-linear finite element analysis results. The paper contains also some recommendation for the implementation of the proposed method in ultimate strength reliability based analysis.
4
Britton, Kyle Anthony, and Zeyun Wu. "A Neutronics Feasibility Study of the TRIGA LEU Fuel in the 20MWt NIST Research Reactor." In 2018 26th International Conference on Nuclear Engineering. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/icone26-82433.
Full textAbstract:
The National Bureau of Standards reactor (NBSR) at the National Institute of Standards and Technology (NIST) is under conversion from high enriched uranium (HEU) to the low enriched uranium (LEU) schema under the Reduced Enrichment for Research and Test Reactors program (RERTR) as a part of the Global Threat Reduction Initiative (GTRI). The conversion of the high performance research reactors (HPRR) such as NBSR is a challenging task due to the high flux need (2.5 × 1014 n/cm2-s for the NBSR), as well as other neutronics performance characteristics requirements without significant changes to the external geometrical configuration. One fuel candidate, the General Atomics (GA) UZrH LEU fuel, has showed particular promise in this regard. The TRIGA LEU fuel was initially developed in the 1980s with particular considerations for fuel conversion for high power regimes such as high density research and test reactors. This study performs a neutronics feasibility study of the UZrH LEU fuel schema for the NBSR, examining the accountability and sustainability of the TRIGA fuel when applying it to the NBSR conversion. To identify the best option to deploy the TRIGA fuel to NBSR in terms of key neutronic performance characteristic, the study is carried out with various considerations in the fuel dimensions, fuel rod layout configurations, and structure material selections. Monte Carlo based computational model is used to assist and facilitate the research procedure. The research findings in this study will determine the viability of the TRIGA fuel type for the NBSR conversion, and provide supporting data for future investigations on this subject.
5
Wang, Biao, Ding Wang, and Yingchu Xie. "Research on the Construction and Application of Burma-Vietnam's Political Event Data Set." In 2018 IEEE 4th International Conference on Big Data Security on Cloud (BigDataSecurity), IEEE International Conference on High Performance and Smart Computing, (HPSC) and IEEE International Conference on Intelligent Data and Security (IDS). IEEE, 2018. http://dx.doi.org/10.1109/bds/hpsc/ids18.2018.00057.
Full text
6
CIMPOIES, Liliana. "SUBSIDIES AND THEIR IMPACT ON THE COMPETITIVENESS OF THE AGRICULTURAL SECTOR IN MOLDOVA." In Rural Development 2015. Aleksandras Stulginskis University, 2015. http://dx.doi.org/10.15544/rd.2015.096.
Full textAbstract:
State support is a major determinant for efficient farm activity that contributes to an increase in the efficiency and quality of production, and contributes to the increase of competitiveness and modernization of agricultural sector. In this paper, the distribution of agricultural subsidies by directions and regions is analyzed. In order to reach the goal and conclude the research tasks the analysis and synthesis of scientific literature, systematization of information, comparative analysis and summarizing methods were used and farm technical efficiency (TE) was calculated. The analyzed period in the given research were 2010–2014, based on primary data collected from corporate farms and secondary data provided by the National Bureau of Statistics, and Agency for Interventions and Payments in Agriculture. During the analyzed period, the amount of allocated subsidies to farmers increased, but still are present inequalities in the distributed funds, difficulties in obtaining the payments and lack of transparency. As well, a clear and consistent policy that could be implemented through the allocation of subsides aimed at developing the agricultural sector is missing.
7
Shchekotilov, V., and O. Lazarev. "Methodology for the use of GIS and archival materials in the preparation of a justification for the recognition of the dead soldiers who were considered missing." In Historical research in the context of data science: Information resources, analytical methods and digital technologies. LLC MAKS Press, 2020. http://dx.doi.org/10.29003/m1830.978-5-317-06529-4/339-345.
Full textAbstract:
A methodology has been proposed and implemented to prepare a justification for the recognition of missing persons as dead. The methodology is based on the use of GIS with archival and commercial maps, as well as archival materials from the database of the Memory of the People system and the Central Archive of the Ministry of Defense. In the quality of the main document, burial
8
Viselli, Anthony M., Andrew J. Goupee, and Habib J. Dagher. "Model Test of a 1:8 Scale Floating Wind Turbine Offshore in the Gulf of Maine." In ASME 2014 33rd International Conference on Ocean, Offshore and Arctic Engineering. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/omae2014-23639.
Full textAbstract:
A new floating wind turbine platform design called VolturnUS developed by the University of Maine uses innovations in materials, construction, and deployment technologies such as a concrete semi-submersible hull and a composite tower to reduce the costs of offshore wind. These novel characteristics require research and development prior to full-scale construction. This paper presents a unique offshore model testing effort aimed at de-risking full-scale commercial projects by providing properly scaled global motion data, allowing for implementation of full-scale structural materials, and demonstrating full-scale construction and deployment methods. The model is a 1:8-scale model of a 6MW semi-submersible floating wind turbine and was deployed offshore Castine, Maine, USA in June, 2013. The model uses a fully operational turbine and was the first grid connected offshore wind turbine in the Americas. The testing effort includes careful treatment of the offshore test site, scaling methods, model design, and construction. A suitable test site was identified that provides the correct proportions of wind and wave loading in order to simulate design load cases prescribed by the American Bureau of Shipping Standard for Building and Classing Floating Offshore Wind Turbines. Sample model test data is provided. Model test data is directly compared to full-scale design predictions made using coupled aeroelastic/ hydrodynamic software. VolturnUS performance data from scaled extreme sea states show excellent agreement with predictive models. Model test data are also compared to a numerical representation of the physical model for the purposes of numerical code validation. The numerical model results compare very favorably with data collected from the physical model.
9
Melchert, Elena Subia, and Roy Clayton Long. "Technologies for Advancing Offshore Enhanced Oil Recovery Capabilities." In Offshore Technology Conference. OTC, 2021. http://dx.doi.org/10.4043/31227-ms.
Full textAbstract:
Abstract Last year the Department of Energy (DOE) presented a description of the expansion of its research portfolio from one focused on research primarily for onshore applications to one that includes projects specifically for offshore application. That paper (OTC - 30469-MS) also included key research results for the portfolio beginning with projects initiated in 2007. This paper follows on that theme and presents an overview of the Department's current research portfolio focusing on recent-past learnings, current learnings, and research gaps identified from the projects in the current research portfolio 2017-2023. Discussion includes projects that are sponsored by the Department as part of its public-private partnerships with principal investigators from industry and academia, and those projects sponsored by the Department at its National Laboratories. The discussion also includes an overview of activities and projects jointly pursued by DOE and the Department of the Interior's Bureau of Safety and Environmental Enforcement (BSEE) pursuant to the July 2020 Memorandum of Collaboration signed by both agencies. Major insights presented in this paper focus on innovative mid-Technology Readiness Level (mid-TRL) technologies that will enable cost-effective enhanced oil recovery in deepwater and ultra-deepwater including insights for cement and wellbore integrity, flow assurance, life extension of offshore platforms and risers, sensors and telecommunications, early kick detection, chemical delivery, data analytics involving big data sets and modeling, and advanced sensors for EOR operations. Many of the projects reviewed in this paper are part of the portfolio of projects that are sponsored by the Department at the National Laboratories while at the same time includes projects that are cost-shared with private sector and research partners in academia. The breadth of the portfolio illustrates the overall approach of the offshore research portfolio especially for enhanced oil recovery. Recently the National Petroleum Council completed a study for the Secretary of Energy titled Meeting the Dual Challenge: A roadmap to at-scale deployment of carbon capture, use, and storage in which the potential for the use and potential long-term storage of CO2 used in enhanced oil recovery is considered for both onshore and offshore settings (NPC 2019).
10
Irvine, Scott R., and M. Kevin Price. "Bureau of Reclamation Activities and Research in Concentrate Management." In World Water and Environmental Resources Congress 2005. American Society of Civil Engineers, 2005. http://dx.doi.org/10.1061/40792(173)300.
Full textReports on the topic "Bureau of Data and Research"
1
Cunningham, Diane. Data bases available at the National Bureau of Standards Research Information Center. National Bureau of Standards, 1986. http://dx.doi.org/10.6028/nbs.ir.86-3428.
Full text
2
Cunningham, Diane, and Carolyn Kline. Data bases available at the National Bureau of Standards Research Information Center. National Bureau of Standards, 1987. http://dx.doi.org/10.6028/nbs.ir.87-3658.
Full text
3
Kramer, Thomas R. Data handling in the vertical workstation of the automated manufacturing research facility at the National Bureau of Standards. National Bureau of Standards, 1988. http://dx.doi.org/10.6028/nbs.ir.88-3763.
Full text
4
Kramer, Thomas R., and Rebecca E. Weaver. The data execution module of the Vertical Workstation of the Automated Manufacturing Research Facility at the National Bureau of Standards. National Bureau of Standards, 1988. http://dx.doi.org/10.6028/nbs.ir.88-3704.
Full text
5
Kramer, Thomas R., and W. Timothy Strayer. Error prevention and detection in data preparation for the Vertical Workstation milling machine in the Automated Manufacturing Research Facility at the National Bureau of Standards. National Bureau of Standards, 1987. http://dx.doi.org/10.6028/nbs.ir.87-3677.
Full text
6
Greenslade, Diana, Andy Taylor, Justin Freeman, et al. Bureau Research Report. Edited by Keith Day. Bureau of Meteorology, 2018. http://dx.doi.org/10.22499/4.0031.
Full text
7
Day, Keith, ed. Bureau Research Report. Bureau of Meteorology, 2017. http://dx.doi.org/10.22499/4.0000.
Full text
8
Wraight, Sarah, Julia Hofmann, Justine Allpress, and Brooks Depro. Environmental justice concerns and the proposed Atlantic Coast Pipeline route in North Carolina. RTI Press, 2018. http://dx.doi.org/10.3768/rtipress.2018.mr.0037.1803.
Full textAbstract:
This report describes publicly available data sets and quantitative analysis that local communities can use to evaluate environmental justice concerns associated with pipeline projects. We applied these data and analytical methods to two counties in North Carolina (Northampton and Robeson counties) that would be affected by the proposed Atlantic Coast Pipeline (ACP). We compared demographic and vulnerability characteristics of census blocks, census block groups, and census tracts that lie within 1 mile of the proposed pipeline route with corresponding census geographies that lie outside of the 1-mile zone. Finally, we present results of a county-level analysis of race and ethnicity data for the entire North Carolina segment of the proposed ACP route. Statistical analyses of race and ethnicity data (US Census Bureau) and Social Vulnerability Index scores (University of South Carolina’s Hazards & Vulnerability Research Institute) yielded evidence of significant differences between the areas crossed by the pipeline and reference geographies. No significant differences were found in our analyses of household income and cancer risk data.
9
Rambo, Neil. Research Data Management. Ithaka S+R, 2015. http://dx.doi.org/10.18665/sr.274643.
Full text
10
Mian, Atif, and Amir Sufi. Household Debt and Defaults from 2000 to 2010: Facts from Credit Bureau Data. National Bureau of Economic Research, 2015. http://dx.doi.org/10.3386/w21203.
Full text